Vivoryon (VVY) | Financial Analysis & Statements
Vivoryon Therapeutics N.V. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Income Metrics
Balance Sheet Metrics
Total Assets
7.5M
Total Liabilities
2.8M
Shareholders Equity
4.7M
Debt to Equity
0.59
Cash Flow Metrics
Revenue & Profitability Trend
Vivoryon Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | -3.6M | 0 | 10.8M |
| Cost of Goods Sold | - | 0 | -525.0K | 0 | 1.6M |
| Gross Profit | - | 0 | -3.1M | 0 | 9.2M |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 85.4% |
| Operating Expenses | |||||
| Research & Development | 4.4M | 14.1M | 17.6M | 20.2M | 17.5M |
| Selling, General & Administrative | 4.8M | 6.9M | 3.3M | 4.9M | 2.4M |
| Other Operating Expenses | - | 3.0K | -42.0K | -54.0K | 100.0K |
| Total Operating Expenses | 9.2M | 21.0M | 20.9M | 25.1M | 19.9M |
| Operating Income | -8.9M | -21.0M | -28.8M | -29.1M | -12.9M |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | -119.8% |
| Non-Operating Items | |||||
| Interest Income | 106.0K | 482.0K | 478.0K | 42.0K | 21.0K |
| Interest Expense | 47.0K | 86.0K | 56.0K | 24.0K | 24.0K |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | -8.9M | -20.6M | -28.6M | -28.4M | -12.2M |
| Income Tax | 0 | 0 | -234.0K | -199.0K | 432.0K |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -8.9M | -20.6M | -28.3M | -28.2M | -12.7M |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | -117.6% |
| Key Metrics | |||||
| EBITDA | -8.7M | -20.3M | -28.4M | -28.2M | -12.0M |
| EPS (Basic) | - | €-0.79 | €-1.12 | €-1.28 | €-0.63 |
| EPS (Diluted) | - | €-0.79 | €-1.12 | €-1.28 | €-0.63 |
| Basic Shares Outstanding | - | 26035443 | 25242140 | 22019557 | 20000014 |
| Diluted Shares Outstanding | - | 26035443 | 25242140 | 22019557 | 20000014 |
Income Statement Trend
Vivoryon Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 5.6M | 9.4M | 18.6M | 26.6M | 14.7M |
| Short-term Investments | 33.0K | 21.0K | 10.0M | 7.0K | 7.0K |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other Current Assets | 775.0K | 639.0K | 495.0K | - | 1.9M |
| Total Current Assets | 6.4M | 10.1M | 29.8M | 30.7M | 20.2M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 121.0K | 142.0K | 159.0K | 157.0K | 150.0K |
| Goodwill | 797.0K | 865.0K | 941.0K | 494.0K | 533.0K |
| Intangible Assets | - | 865.0K | 941.0K | 494.0K | 533.0K |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 173.0K | 228.0K | - | - | - |
| Total Non-Current Assets | 1.1M | 1.2M | 1.0M | 684.0K | 4.3M |
| Total Assets | 7.5M | 11.3M | 30.8M | 31.4M | 24.5M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 458.0K | 1.0M | 2.9M | 2.5M | 4.4M |
| Short-term Debt | 64.0K | 60.0K | 38.0K | 94.0K | 92.0K |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 315.0K | 324.0K | 1.0K | 6.0K | 3.0K |
| Total Current Liabilities | 837.0K | 1.4M | 3.2M | 3.3M | 5.1M |
| Non-Current Liabilities | |||||
| Long-term Debt | 44.0K | 42.0K | 0 | 38.0K | 132.0K |
| Deferred Tax Liabilities | - | - | 0 | 234.0K | 432.0K |
| Other Non-Current Liabilities | - | -1.0K | - | - | 513.0K |
| Total Non-Current Liabilities | 2.0M | 2.0M | 1.4M | 1.6M | 2.9M |
| Total Liabilities | 2.8M | 3.4M | 4.5M | 4.9M | 8.0M |
| Equity | |||||
| Common Stock | 296.0K | 261.0K | 26.1M | 24.1M | 20.0M |
| Retained Earnings | -178.2M | -169.4M | -148.8M | -120.5M | -92.3M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 4.7M | 7.9M | 26.3M | 26.5M | 16.6M |
| Key Metrics | |||||
| Total Debt | 108.0K | 102.0K | 38.0K | 132.0K | 224.0K |
| Working Capital | 5.6M | 8.7M | 26.6M | 27.4M | 15.2M |
Balance Sheet Composition
Vivoryon Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -8.9M | -20.6M | -28.3M | -28.2M | -12.7M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | 893.0K | 2.2M | 3.9M | 3.5M | 1.8M |
| Working Capital Changes | -90.0K | 294.0K | -679.0K | 2.9M | -3.9M |
| Operating Cash Flow | -8.1M | -18.5M | -22.4M | -19.1M | -15.0M |
| Investing Activities | |||||
| Capital Expenditures | -6.0K | -2.0K | -14.0K | -11.0K | -20.0K |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | 0 | 0 | -19.0M | 0 | - |
| Investment Sales | 0 | 10.0M | 9.0M | 0 | - |
| Investing Cash Flow | -6.0K | 10.0M | -10.0M | -11.0K | -20.0K |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | 4.8M | 0 | 24.3M | 34.2M | 1.1M |
| Free Cash Flow | -8.5M | -19.2M | -22.1M | -21.8M | -11.3M |
| Net Change in Cash | -3.3M | -8.5M | -8.2M | 15.1M | -13.8M |
Cash Flow Trend
Vivoryon Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-1.58
Forward P/E
-3.27
Price to Book
11.07
PEG Ratio
-3.27
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-145.47%
Return on Assets
-67.68%
Financial Health
Current Ratio
4.04
Debt to Equity
2.26
Beta
1.44
Per Share Data
EPS (TTM)
€-0.48
Book Value per Share
€0.12
Revenue per Share
€0.00
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| VVY | 37.0M | -1.58 | 11.07 | -145.47% | 0.00% | 2.26 |
| Galapagos NV | 1.6B | 5.10 | 0.50 | 10.42% | 28.85% | 0.21 |
| Pharming Group N.V | 1.0B | 57.15 | 4.31 | 1.02% | 0.76% | 41.78 |
| Koninklijke Philips | 22.2B | 25.04 | 2.02 | 7.82% | 5.02% | 73.57 |
Financial data is updated regularly. All figures are in the company's reporting currency.